191 related articles for article (PubMed ID: 8943658)
1. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
Cunningham D
Eur J Cancer; 1996; 32A Suppl 3():S1-8. PubMed ID: 8943658
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
Shimada Y; Rougier P; Pitot H
Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
[TBL] [Abstract][Full Text] [Related]
3. CPT-11 (irinotecan) in the treatment of colorectal cancer.
Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
[TBL] [Abstract][Full Text] [Related]
4. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
Saltz L; Shimada Y; Khayat D
Eur J Cancer; 1996; 32A Suppl 3():S24-31. PubMed ID: 8943662
[TBL] [Abstract][Full Text] [Related]
5. CPT-11 in gastrointestinal cancer.
Bleiberg H
Eur J Cancer; 1999 Mar; 35(3):371-9. PubMed ID: 10448285
[TBL] [Abstract][Full Text] [Related]
6. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
[TBL] [Abstract][Full Text] [Related]
7. CPT-11: an original spectrum of clinical activity.
Rothenberg ML
Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
[TBL] [Abstract][Full Text] [Related]
8. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
[TBL] [Abstract][Full Text] [Related]
9. The role of irinotecan in colorectal cancer.
Saltz LB
Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the use of irinotecan in colorectal cancer.
Cunningham D; Maroun J; Vanhoefer U; Van Cutsem E
Oncologist; 2001; 6 Suppl 4():17-23. PubMed ID: 11585970
[TBL] [Abstract][Full Text] [Related]
11. Role of chemotherapy for advanced colorectal cancer: new opportunities.
Bleiberg H
Semin Oncol; 1996 Feb; 23(1 Suppl 3):42-50. PubMed ID: 8633253
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan in the first-line treatment of colorectal cancer.
Saltz LB
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
15. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Lavrenkov K; Man S; Mermershtain W; Cohen Y
J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
[TBL] [Abstract][Full Text] [Related]
18. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
19. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
Rougier P; Bugat R
Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
[TBL] [Abstract][Full Text] [Related]
20. Update on European adjuvant trials with irinotecan for colorectal cancer.
Douillard JY; Barbarot V; Bennouna J
Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
